Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.39 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | HTR1B | P28222 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 5/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30394068 | 0.92 | HTR1B (0.43) | MAPTL3MBTL1HPGDRAB9ANPC1 | |
| SCHEMBL19897937 | 0.92 | HTR1B (0.43) | MAPTL3MBTL1HPGDRAB9ANPC1 | |
| SCHEMBL18728167 | 0.90 | HTR7 (0.43) | MAPTL3MBTL1HPGDRAB9ANPC1 | |
| SCHEMBL29648252 | 0.90 | HTR7 (0.43) | MAPTL3MBTL1HPGDRAB9ANPC1 | |
| SCHEMBL26636424 | 0.85 | HTR7 (0.42) | MAPTL3MBTL1HPGDRAB9ANPC1 | |
| SCHEMBL28469003 | 0.84 | HTR1B (0.45) | MAPTL3MBTL1HPGDRAB9ANPC1 | |
| SCHEMBL30394884 | 0.84 | HTR1B (0.45) | MAPTL3MBTL1HPGDRAB9ANPC1 | |
| SCHEMBL26636905 | 0.81 | HTR7 (0.44) | MAPTL3MBTL1HPGDRAB9ANPC1 | |
| Bicarbonate SCHEMBL29992844 | 0.80 | SMN1; SMN2 (0.39) | MAPTL3MBTL1HPGDRAB9ANPC1 | |
| SCHEMBL21359629 | 0.80 | CD274 (0.49) | MAPTHTR1BCD274S1PR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11485708-B2 | Compounds for treatment of PD-L1 diseases | CHEMOCENTRYX, INC. (US) | 2022-11-01 | — | — | US | disclosed |
| EP-3986392-A2 | COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | ChemoCentryx, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| US-20210002229-A1 | COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. | 2021-01-07 | — | — | US | disclosed |
| WO-2020257549-A2 | COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020257549-A2 | COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002229-A1 | COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | CD274, PDCD1, PDCD1LG2 | MAPT 3250/4885L3MBTL1 568/4885HPGD 2451/4885 |
| US-11485708-B2 | Compounds for treatment of PD-L1 diseases | CD274, PDCD1, PDCD1LG2 | MAPT 3250/4885L3MBTL1 568/4885HPGD 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.